Precision medicine has transformed oncology, but the next wave is unfolding in new therapeutic areas. The expansion into new areas promises enormous impact, yet the path forward is not straightforward. Outside of oncology, patient populations are more heterogeneous, biomarkers less validated, and regulatory and payor expectations less defined. Unlike oncology, where validated genetic drivers define patient groups, chronic and brain health conditions often lack clear biological anchors. This session will examine the big-picture opportunities and roadblocks for precision medicine’s expansion. Panelists will explore the evolving regulatory framework, payer readiness, and the tools - ranging from digital diagnostics to AI - that could enable precision care at scale. The discussion will draw lessons from oncology’s playbook while highlighting the unique considerations that must be addressed to translate precision into practice across new therapeutic domains.